Ignite Creation Date:
2024-05-05 @ 6:36 PM
Last Modification Date:
2024-10-26 @ 9:35 AM
Study NCT ID:
NCT00516685
Status:
TERMINATED
Last Update Posted:
2011-09-30
First Post:
2007-08-14
Brief Title:
Vaccine Therapy in Treating Patients With Non-Small Cell Lung Cancer NSCLC Stages IIIBIV
Sponsor:
Bioven Sdn Bhd
Organization:
Bioven Sdn Bhd
Study Overview
Official Title:
A Phase IIIII Trial to Assess the Safety Immunogenicity and Preliminary Efficacy of Recombinant Human EGF-rP64KMontanide ISA 51 Vaccine Administered to Patients With Non-Small-Cell Lung Cancer NSCLC After Receiving Conventional First Line Chemotherapy
Status:
TERMINATED
Status Verified Date:
2011-09
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Due to inability of patient enrollment decision taken to terminate in the interests of patients and later Malaysia is incorporated into global Phase 3 trial
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
NSCLC
Brief Summary:
The purpose of this study is to determine whether the recombinant human EGF-rP64KMontanide ISA 51 vaccine is safe immunogenic and effective in the treatment of stage IIIbIV non-small-cell lung cancer NSCLC
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None